COVID-19 vaccination in pregnancy-number needed to vaccinate to avoid harm.
Ontology highlight
ABSTRACT:
SUBMITTER: Magee LA
PROVIDER: S-EPMC8563006 | biostudies-literature |
REPOSITORIES: biostudies-literature
Similar Datasets
Project description:The supply limitations of COVID-19 vaccines have led to the need to prioritize vaccine distribution. Obesity, diabetes, and hypertension have been associated with an increased risk of severe COVID-19 infection. Approximately half as many individuals with a cardiovascular risk factor need to be vaccinated against COVID-19 to prevent related death compared with individuals without a risk factor. Adults with body mass index ≥ 30, diabetes, or hypertension should be of a similar priority for COVID-19 vaccination to adults 10 years older with a body mass index of 20 to < 30, no diabetes, and no hypertension.
| S-EPMC8084283 | biostudies-literature
Project description:Researcher teams around the globe including the "Project Lightspeed" are intensively working on vaccines to fight the Covid-19 pandemic. However, the availability of effective vaccines does not guarantee the vaccination willingness among the population. In spring 2021, we investigated the vaccination willingness and its potential predictors in representative online samples in nine countries (China, France, Germany, Poland, Russia, Spain, Sweden, U.K., U.S.). Of the 9,264 participants, 79.9% revealed Covid-19 vaccination willingness. The highest willingness was in the U.K., followed by Spain and China, the lowest in Russia. In most countries, the perception of governmental Covid-19 measures as useful and the use of television reports as Covid-19 information source positively predicted the willingness. Further factors such as demographic variables, mental and physical health status, evaluation of governmental communication, social media use, and general adherence to Covid-19 measures showed a country-specific predictive pattern. Recommendations how to increase the vaccination willingness are provided.
| S-EPMC8635370 | biostudies-literature
Project description: Not available
| S-EPMC8427483 | biostudies-literature
Project description:To assess trends in and factors associated with COVID-19 vaccination (≥ 1 dose) coverage, data from the Household Pulse Survey were analyzed. From April-August 2021, vaccination coverage with at least one dose increased from 70% to 82%, while vaccination intent increased from 82% to 86%, with the highest increase among the most vulnerable groups. More efforts are needed to boost confidence in vaccines and to encourage all eligible people to be fully vaccinated.
| S-EPMC8715625 | biostudies-literature
Project description:Objective:Schizophrenia clinical trials commonly measure observed changes in Positive and Negative Syndrome Scale (PANSS) total score. However, it is more intuitive to think of response vs nonresponse, a binary outcome. Assessing binary outcomes enables calculation of number needed to treat (NNT) for therapeutic outcomes, number needed to harm (NNH) for adverse outcomes, and likelihood to be helped or harmed (LHH) to demonstrate benefit/risk tradeoffs. Here, NNT, NNH, and LHH were used to evaluate the clinical usefulness of aripiprazole lauroxil in patients with an acute schizophrenia exacerbation. Methods:Categorical efficacy and tolerability data were taken from the pivotal Phase 3 trial evaluating aripiprazole lauroxil for treatment of an acute exacerbation of schizophrenia. NNT and NNH values, with 95% CIs, were calculated in this post hoc analysis. Results:Using the intent-to-treat population for the pooled doses of aripiprazole lauroxil (441 mg [n=196] and 882 mg [n=204] q4w), responder rates (?30% improvement from baseline PANSS total score) were 35.3% for aripiprazole lauroxil arms vs 18.4% for placebo (n=196), yielding a NNT of 6 (95% CI: 5-11). Discontinuation rates due to adverse events (AEs) were higher among patients randomized to placebo than to either aripiprazole lauroxil dose. Akathisia was the only AE with an incidence ?5% in each aripiprazole lauroxil group and at least twice that of placebo (11.6%, 11.5%, and 4.3% of the patients receiving aripiprazole lauroxil 441 mg, 882 mg, and placebo, respectively), producing a NNH of 14 (95% CI: 9-33) for pooled aripiprazole lauroxil doses vs placebo. Calculating LHH for therapeutic response vs akathisia, aripiprazole lauroxil was 2.3 times more likely to result in a therapeutic response than an incident of akathisia. Conclusion:Using metrics of NNT, NNH, and LHH, aripiprazole lauroxil was an efficacious and well-tolerated intervention in a pivotal study in patients with an acute schizophrenia exacerbation.
| S-EPMC6751763 | biostudies-literature
Project description:BackgroundA vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now licensed for use in Canada and many other countries. We sought to estimate the number needed to vaccinate to prevent HPV-related diseases and death.MethodsA cohort model of the natural history of HPV infection was developed. Model simulations were based on 209 different parameter sets that reproduced Canadian HPV type-specific data for infection, cervical intraepithelial neoplasia, cervical cancer and genital warts. The number needed to vaccinate was calculated as the number of women who would need to be vaccinated to prevent an HPV-related event during their lifetime.ResultsAmong 12-year-old girls, we estimated that the number needed to vaccinate to prevent an episode of genital warts would be 8 (80% credibility interval [CrI] 5-15) and a case of cervical cancer 324 (80% CrI 195-757). These estimates were based on the assumption that the vaccine procures lifelong protection and that its efficacy is 95%. If vaccine protection is assumed to wane at 3% per year, the predicted number needed to vaccinate would increase to 14 (80% CrI 6-18) and 9080 (80% CrI 1040-does not prevent), respectively. The latter number would be greatly reduced with the addition of a booster dose, to 480 (80% CrI 254-1572).InterpretationOur model predictions suggest that vaccination with the currently available HPV vaccine may significantly reduce the incidence of genital warts, cervical intraepithelial neoplasia and cervical cancer. However, the benefits (particularly in terms of cervical cancer reduction) are highly dependent on the duration of vaccine protection, on which evidence is currently limited.
| S-EPMC1950193 | biostudies-literature
Project description: Not available
| S-EPMC8552533 | biostudies-literature
Project description: Not available
| S-EPMC7489926 | biostudies-literature
Project description:Despite global efforts to rapidly distribute COVID-19 vaccines, early estimates suggested that 29–35% of the population were hesitant/unwilling to receive them. Countering such vaccine hesitancy is thus an important priority. Across two sets of online studies (total n = 1584) conducted in the UK before (August–October 2020) and immediately after the first effective vaccine was publicly announced (November 10–19, 2020), brief exposure (<1 min) to vaccination memes boosted the potentially life-saving intention to vaccinate against COVID-19. These intention-boosting effects, however, weakened once a COVID-19 vaccine became a reality (i.e., after the announcement of a safe/effective vaccine), suggesting meme-based persuasion may be context-dependent. These findings thus represent preliminary evidence that naturally circulating memes may—under certain circumstances—influence public intentions to vaccinate, although more research regarding this context-specificity as well as the potential psychological mechanisms through which memes act is needed.
| S-EPMC8803897 | biostudies-literature
Project description: Not available
| S-EPMC9258750 | biostudies-literature